NYSE$USPH

US Physical Therapy Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Reported record-high patient volume and increased revenue driven by clinic additions and mature clinic visits.

U.S. Physical Therapy reported a 7.5% increase in total net revenue to $150.0 million, driven by a 9.0% increase in net patient revenue from physical therapy operations. The company achieved a record-high average visits per clinic per day for a third quarter, with total patient visits up 10.8%. EPS was $0.51, and non-GAAP Operating Results per share were $0.62.

  • Adjusted EBITDA increased to $18.6 million, up from $17.0 million in the prior year.
  • Net patient revenue from physical therapy operations rose 9.0% to $127.2 million.
  • Average visits per clinic per day reached a record-high of 29.7.
  • Operating costs per patient visit decreased by 0.8%.

Headline financials

Total Revenue

$150M

Previous: $140M+7.5%
EPS (adj)

$0.62

Previous: $0.58+6.9%
Net Rate per Visit

$102.37

Previous: $104.01-1.6%
Capital Expenditures

-$2.55M

No prior period
Free Cash Flow

$9.25M

Previous: $9.56M-3.2%
Net Income

$9.25M

Previous: $9.56M-3.2%
Operating Income

$15.9M

Previous: $14.9M+6.6%
Gross Profit

$27.9M

Previous: $26.8M+4.3%
Cash & Equivalents

$148M

Previous: $37.9M+289.5%
Total Assets

$1.01B

Previous: $800M+26.3%
Stock-Based Comp

$1.86M

Previous: $1.8M+3.2%

Revenue & EPS history

US Physical Therapy · Revenue · Quarterly

$150M

Q3 2023+7.5%vs Q3 2022
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Revenue by segment

US Physical Therapy · $128M total across 1 segment · Q3 2023

  • Physical Therapy Operations
    $128M+9.1%

Forward guidance

Management expects Adjusted EBITDA for 2023 to be within the range of $75.0 million to $80.0 million, most likely at the low-to-mid area of such range.

Tailwinds

  • Continued strong patient visits through the end of the year.
  • Potential for growth in net rate from the third to the fourth quarter.
  • Focus on initiative to drive greater progress in net rate.
  • Balance sheet in an outstanding position with $149 million of debt fixed at a below-market rate
  • Approximately $120 million of excess cash ready for deployment into growth initiatives

Headwinds

  • Ultimate strength of volumes in the fourth quarter depends on Adjusted EBITDA.
  • Medicare rate reductions.
  • Inflationary impacts.
  • Challenging hiring environment.
  • Medicare rate reductions

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-0.6%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-1.5%

Avg return

30 days after

53%

35 / 66 earnings

Positive

+17.3%

Q3 2024

Best reaction

-27.5%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.5%+1.3%
Q4 2025-2.9%+1.9%-8.5%
Q3 2025+0.9%-15.8%-13.8%
Q2 2025+14.7%+20.4%+17.8%
Q1 2025-0.1%+8.8%+8.9%
Q4 2024-6.0%-9.5%-18.0%
Q3 2024+17.3%+14.8%+17.9%
Q2 2024-6.8%-3.9%-5.4%
Q1 2024-2.2%+0.2%-8.0%
Q4 2023+3.4%+2.8%+9.8%
Q3 2023-2.8%-3.3%+4.3%
Q2 2023-8.6%-8.1%-19.8%
Q1 2023+4.5%+10.1%+2.1%
Q4 2022+2.1%+2.2%-5.7%
Q3 2022-8.9%-4.0%-0.3%
Q2 2022-27.5%-29.9%-37.0%
Q1 2022-4.4%-4.1%+4.2%
Q4 2021-5.8%-6.5%-2.1%
Q3 2021-3.6%-8.2%-21.6%
Q2 2021-3.6%-5.4%-1.1%
Q1 2021+6.0%+4.5%+6.6%
Q4 2020-17.2%-19.8%-24.3%
Q3 2020+8.4%+26.6%+29.2%
Q2 2020+2.4%+1.1%+3.7%
Q1 2020-1.0%+2.7%+0.9%
Q4 2019-17.7%-16.0%-49.0%
Q3 2019-20.1%-20.4%-20.5%
Q2 2019+3.9%+6.1%+8.1%
Q1 2019+2.3%+3.3%-1.2%
Q4 2018+3.2%+3.4%+2.1%
Q3 2018+5.1%+6.5%+10.7%
Q2 2018+8.9%+7.0%+18.9%
Q1 2018-1.4%-0.5%+2.4%
Q4 2017+6.8%+2.7%+4.9%
Q3 2017-2.6%-2.9%+5.7%
Q2 2017+2.4%+2.6%-2.9%
Q1 2017-6.0%+0.8%-2.1%
Q4 2016+1.7%+2.0%-1.2%
Q3 2016-1.2%+0.5%+14.3%
Q2 2016+4.7%+4.0%+9.7%
Q1 2016+12.7%
Q4 2015+1.2%
Q3 2015+2.3%
Q2 2015-5.0%
Q1 2015+7.9%
Q4 2014+5.4%
Q3 2014-7.2%
Q2 2014+5.8%
Q1 2014+3.0%
Q4 2013-0.3%
Q3 2013-7.1%
Q2 2013+6.0%
Q1 2013+3.5%
Q4 2012-4.6%
Q3 2012+0.6%
Q2 2012+0.6%
Q1 2011+1.0%
Q1 2012+2.1%
Q4 2009-0.2%
Q4 2011-0.2%
Q3 2010+1.9%
Q3 2011+1.9%
Q2 2011-10.9%
Q4 2010-10.9%
Q2 2010-10.9%
Q1 2010+12.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro